Relevance of Comet Assay and Phosphorylated-Hsp90α in Cancer Patients' Peripheral Blood Leukocytes as Tools to Assess Cisplatin-based Chemotherapy Clinical Response and Disease Outcome
Cisplatin (cPt) is a commonly used treatment for solid tumors. The main target of its cytotoxicity is the DNA molecule, which makes the DNA damage response (DDR) crucial for cPt-based chemotherapy. Therefore, it is essential to identify biomarkers that can accurately predict the individual clinical...
Uloženo v:
| Vydáno v: | The journal of histochemistry and cytochemistry Ročník 72; číslo 3; s. 173 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.03.2024
|
| Témata: | |
| ISSN: | 1551-5044, 1551-5044 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cisplatin (cPt) is a commonly used treatment for solid tumors. The main target of its cytotoxicity is the DNA molecule, which makes the DNA damage response (DDR) crucial for cPt-based chemotherapy. Therefore, it is essential to identify biomarkers that can accurately predict the individual clinical response and prognosis. Our goal was to assess the usefulness of alkaline comet assay and immunocytochemical staining of phosphorylated Hsp90α (p-Hsp90α), γH2AX, and 53BP1 as predictive/prognostic markers. Pre-chemotherapy peripheral blood leukocytes were exposed to cPt in vitro and collected at 0, 24 (T24), and 48 (T48) hr post-drug removal. Healthy subjects were also included. Baseline DNA damage was elevated in cancer patients (variability between individuals was observed). After cPt, patients showed increased γH2AX foci/nucleus (T24 and T48). Both in healthy persons and patients, the nuclear p-Hsp90α and N/C (nuclear/cytoplasmic) ratio augmented (T24), decreasing at T48. Favorable clinical response was associated with high DNA damage and p-Hsp90α N/C ratio following cPt. For the first time, p-Hsp90α significance as a predictive marker is highlighted. Post-cPt-DNA damage was associated with longer disease-free survival and overall survival. Our findings indicate that comet assay and p-Hsp90α (a marker of DDR) would be promising prognostic/predictive tools in cP-treated cancer patients. |
|---|---|
| AbstractList | Cisplatin (cPt) is a commonly used treatment for solid tumors. The main target of its cytotoxicity is the DNA molecule, which makes the DNA damage response (DDR) crucial for cPt-based chemotherapy. Therefore, it is essential to identify biomarkers that can accurately predict the individual clinical response and prognosis. Our goal was to assess the usefulness of alkaline comet assay and immunocytochemical staining of phosphorylated Hsp90α (p-Hsp90α), γH2AX, and 53BP1 as predictive/prognostic markers. Pre-chemotherapy peripheral blood leukocytes were exposed to cPt in vitro and collected at 0, 24 (T24), and 48 (T48) hr post-drug removal. Healthy subjects were also included. Baseline DNA damage was elevated in cancer patients (variability between individuals was observed). After cPt, patients showed increased γH2AX foci/nucleus (T24 and T48). Both in healthy persons and patients, the nuclear p-Hsp90α and N/C (nuclear/cytoplasmic) ratio augmented (T24), decreasing at T48. Favorable clinical response was associated with high DNA damage and p-Hsp90α N/C ratio following cPt. For the first time, p-Hsp90α significance as a predictive marker is highlighted. Post-cPt-DNA damage was associated with longer disease-free survival and overall survival. Our findings indicate that comet assay and p-Hsp90α (a marker of DDR) would be promising prognostic/predictive tools in cP-treated cancer patients. Cisplatin (cPt) is a commonly used treatment for solid tumors. The main target of its cytotoxicity is the DNA molecule, which makes the DNA damage response (DDR) crucial for cPt-based chemotherapy. Therefore, it is essential to identify biomarkers that can accurately predict the individual clinical response and prognosis. Our goal was to assess the usefulness of alkaline comet assay and immunocytochemical staining of phosphorylated Hsp90α (p-Hsp90α), γH2AX, and 53BP1 as predictive/prognostic markers. Pre-chemotherapy peripheral blood leukocytes were exposed to cPt in vitro and collected at 0, 24 (T24), and 48 (T48) hr post-drug removal. Healthy subjects were also included. Baseline DNA damage was elevated in cancer patients (variability between individuals was observed). After cPt, patients showed increased γH2AX foci/nucleus (T24 and T48). Both in healthy persons and patients, the nuclear p-Hsp90α and N/C (nuclear/cytoplasmic) ratio augmented (T24), decreasing at T48. Favorable clinical response was associated with high DNA damage and p-Hsp90α N/C ratio following cPt. For the first time, p-Hsp90α significance as a predictive marker is highlighted. Post-cPt-DNA damage was associated with longer disease-free survival and overall survival. Our findings indicate that comet assay and p-Hsp90α (a marker of DDR) would be promising prognostic/predictive tools in cP-treated cancer patients.Cisplatin (cPt) is a commonly used treatment for solid tumors. The main target of its cytotoxicity is the DNA molecule, which makes the DNA damage response (DDR) crucial for cPt-based chemotherapy. Therefore, it is essential to identify biomarkers that can accurately predict the individual clinical response and prognosis. Our goal was to assess the usefulness of alkaline comet assay and immunocytochemical staining of phosphorylated Hsp90α (p-Hsp90α), γH2AX, and 53BP1 as predictive/prognostic markers. Pre-chemotherapy peripheral blood leukocytes were exposed to cPt in vitro and collected at 0, 24 (T24), and 48 (T48) hr post-drug removal. Healthy subjects were also included. Baseline DNA damage was elevated in cancer patients (variability between individuals was observed). After cPt, patients showed increased γH2AX foci/nucleus (T24 and T48). Both in healthy persons and patients, the nuclear p-Hsp90α and N/C (nuclear/cytoplasmic) ratio augmented (T24), decreasing at T48. Favorable clinical response was associated with high DNA damage and p-Hsp90α N/C ratio following cPt. For the first time, p-Hsp90α significance as a predictive marker is highlighted. Post-cPt-DNA damage was associated with longer disease-free survival and overall survival. Our findings indicate that comet assay and p-Hsp90α (a marker of DDR) would be promising prognostic/predictive tools in cP-treated cancer patients. |
| Author | Gómez, Laura C Gonzalez, Lucía Ibarra, Jorge Vargas-Roig, Laura M Redondo, Analía Sottile, Mayra L García, María B Nadin, Silvina B |
| Author_xml | – sequence: 1 givenname: Mayra L surname: Sottile fullname: Sottile, Mayra L organization: Medical Sciences School, Mendoza University, Mendoza, Argentina – sequence: 2 givenname: Laura C surname: Gómez fullname: Gómez, Laura C organization: Medical Sciences School, Mendoza University, Mendoza, Argentina – sequence: 3 givenname: Analía surname: Redondo fullname: Redondo, Analía organization: Tumor Biology Laboratory, Institute of Medicine and Experimental Biology of Cuyo, National Scientific and Technical Research Council, National University of Cuyo, Mendoza, Argentina – sequence: 4 givenname: Jorge surname: Ibarra fullname: Ibarra, Jorge organization: Regional Integration Cancer Center, Mendoza, Argentina – sequence: 5 givenname: María B surname: García fullname: García, María B organization: Regional Integration Cancer Center, Mendoza, Argentina – sequence: 6 givenname: Lucía surname: Gonzalez fullname: Gonzalez, Lucía organization: Regional Integration Cancer Center, Mendoza, Argentina – sequence: 7 givenname: Laura M surname: Vargas-Roig fullname: Vargas-Roig, Laura M organization: Tumor Biology Laboratory, Institute of Medicine and Experimental Biology of Cuyo, National Scientific and Technical Research Council, National University of Cuyo, Mendoza, Argentina – sequence: 8 givenname: Silvina B orcidid: 0000-0002-1109-3156 surname: Nadin fullname: Nadin, Silvina B organization: Tumor Biology Laboratory, Institute of Medicine and Experimental Biology of Cuyo, National Scientific and Technical Research Council, National University of Cuyo, Mendoza, Argentina |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38439738$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1u1EAQhVsoEfmBA7BBtSMbk_7zuHsZTCBII2UUhfWo3S5rGuxu42oj-VgsuQRnwgNBYlNVT3rv01NdsJOYIjL2SvC3Qm3sNedSirLUUgupNut8xs5XLYqSa33y333GLoi-cC60Ls1zdqaMVrZS5pz9fMAev7voEVIHdRowww2RW8DFFnaHROMhTUvvMrbFHY2W__oBIUJ9jEywczlgzPQGdjiF8YCT6-Fdn1ILW5y_Jr9kJHAEjyn1BDkd4UgEdaBxhYZYNI6whfqAQ8rH_LhA3YcY_Ep6QBpTJPxT5n0gXL1wP2e_9nzBTjvXE7582pfs84fbx_qu2N5__FTfbAuvrMiF3zglDe8s997bjnPdGFGh8K0S0jaNdEY7pztUjauELr1prDIbZxRWnbdWXrKrv9xxSt9mpLwfAnnsexcxzbSXVlUV10ap1fr6yTo3A7b7cQqDm5b9v3fL32Erh68 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1369/00221554241236241 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology |
| EISSN | 1551-5044 |
| ExternalDocumentID | 38439738 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -TM -~X .2E .2J .2N .55 .GJ 01A 0R~ 18M 1~K 29K 2WC 3O- 4.4 54M 5GY 5RE 5VS 85S AABMB AABOD AACKU AACMV AACTG AADUE AAEJI AAEWN AAGGD AAGLT AAGMC AAJIQ AAJOX AAJPV AAKGS AANSI AAPEO AAPII AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAYTG ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHKI ABIDT ABJIS ABJNI ABJZC ABKRH ABLUO ABOCM ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABVFX ABVVC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACGBL ACGFS ACGZU ACJER ACJTF ACLFY ACLHI ACLZU ACNCT ACOFE ACOXC ACROE ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEBD ADEIA ADNON ADNWM ADRRZ ADTBJ ADUKL ADVBO ADXHL ADZZY AECGH AECVZ AEDTQ AEKYL AENEX AEPTA AEQLS AERKM AESZF AETEA AEUHG AEWDL AEWHI AEXNY AFEET AFFNX AFKBI AFKRG AFMOU AFQAA AFUIA AGHKR AGKLV AGNHF AGPXR AGWFA AHDMH AHJOV AI. AJEFB AJGYC AJMMQ AJUZI AJVBE AJXAJ ALKWR ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV AUTPY AUVAJ AYAKG B3H B8M B8R B8Z B94 BAWUL BBRGL BDDNI BKIIM BKSCU BPACV BSEHC BWJAD BYIEH C1A C45 CBRKF CDWPY CFDXU CGR CORYS CQQTX CS3 CUY CVF D-I DB0 DC- DD- DD0 DE- DE. DF0 DIK DN0 DO- DOPDO DU5 DV7 E3Z EBS ECM EIF EJD F5P FHBDP GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GX1 H13 HF~ HH5 HZ~ H~9 IH2 J5H J8X K.F L7B MVM NPM O9- OHT OK1 OVD P.9 P.B P2P Q1R Q7L Q7U Q83 ROL S01 SASJQ SAUOL SCNPE SFC SHG SPQ SPV TEORI THC TN5 TR2 UHB UPT UQL VH1 W8F WH7 WOQ X7M YBU YHG YQT YWH ZGI ZONMY ZPPRI ZRKOI ZSSAH 7X8 ABUFD AJHME |
| ID | FETCH-LOGICAL-c391t-c6a3280f90ccc9f004b817e1cd3129bb2a84aa4fe3ba7145c8b9386a83e7fc992 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001179694200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1551-5044 |
| IngestDate | Sun Nov 09 09:27:08 EST 2025 Mon Jul 21 05:55:34 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | human leukocytes phospho-Hsp90α prognostic markers 53BP1 DNA damage predictive markers γH2AX platinum analogues oncology |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c391t-c6a3280f90ccc9f004b817e1cd3129bb2a84aa4fe3ba7145c8b9386a83e7fc992 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-1109-3156 |
| OpenAccessLink | https://pmc.ncbi.nlm.nih.gov/articles/PMC10956442/pdf/10.1369_00221554241236241.pdf |
| PMID | 38439738 |
| PQID | 2937704833 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2937704833 pubmed_primary_38439738 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-00 20240301 |
| PublicationDateYYYYMMDD | 2024-03-01 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The journal of histochemistry and cytochemistry |
| PublicationTitleAlternate | J Histochem Cytochem |
| PublicationYear | 2024 |
| SSID | ssj0014458 |
| Score | 2.4169319 |
| Snippet | Cisplatin (cPt) is a commonly used treatment for solid tumors. The main target of its cytotoxicity is the DNA molecule, which makes the DNA damage response... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 173 |
| SubjectTerms | Cisplatin - pharmacology Cisplatin - therapeutic use Comet Assay DNA Damage Humans Leukocytes Neoplasms - drug therapy Neoplasms - genetics |
| Title | Relevance of Comet Assay and Phosphorylated-Hsp90α in Cancer Patients' Peripheral Blood Leukocytes as Tools to Assess Cisplatin-based Chemotherapy Clinical Response and Disease Outcome |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38439738 https://www.proquest.com/docview/2937704833 |
| Volume | 72 |
| WOSCitedRecordID | wos001179694200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagBYkLjxZoeWmQEJwsNnEa2ydUFqoeYFlVRdrbyk-xYonTdRYpP6tH_gS_ibGTqickJC65ObIy45kvnm_mI-SVq01hvGVUIl6lVV1LKp1nVHOhLZdKWe6z2ASfzcRiIefjhVscaZVXMTEHahtMuiN_i2mJ8zT_nL1rL2hSjUrV1VFC4ybZZQhlEqWLL66rCFWV9TkTKqBHk6oaq5qslqkLvEypFBNYiTG8Kv6OMHOmObn3v3u8T-6OGBOOB6d4QG64Zo_sHzf4f_2jh9eQWZ_5On2P3B7EKPt98usstZonJ4DgAeOE6wCNp3pQjcU1IbbfwqZfIzi19DS2cvL7ElYNTNOSDcyHAa3xDczRqfOwgjW8T7R4-OS234PpEdSCinAewjpCF2CoN8N0FdtEyGtoyqgW0giDsS2sh3Fs6RrOBi6vy5v5MFSV4Mu2ww_jHpKvJx_Pp6d0FHaghsmio6ZWrBQTLyfGGOnxnGpRcFcYyxB-aF0qUSlVece04kV1ZISWTNRKMMe9kbJ8RHaa0LgDAlwb7ywrVZ3E1IwQNWOlNkZYfIss3CF5eWWqJR6cVA1RjQvbuLw21iF5PNh72Q4TPpZMJJzGxJN_WP2U3CkR6Ay8tGdk12PYcM_JLfOzW8XNi-yR-JzNP_8BKsPu-g |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relevance+of+Comet+Assay+and+Phosphorylated-Hsp90%CE%B1+in+Cancer+Patients%27+Peripheral+Blood+Leukocytes+as+Tools+to+Assess+Cisplatin-based+Chemotherapy+Clinical+Response+and+Disease+Outcome&rft.jtitle=The+journal+of+histochemistry+and+cytochemistry&rft.au=Sottile%2C+Mayra+L&rft.au=G%C3%B3mez%2C+Laura+C&rft.au=Redondo%2C+Anal%C3%ADa&rft.au=Ibarra%2C+Jorge&rft.date=2024-03-01&rft.issn=1551-5044&rft.eissn=1551-5044&rft.volume=72&rft.issue=3&rft.spage=173&rft_id=info:doi/10.1369%2F00221554241236241&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1551-5044&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1551-5044&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1551-5044&client=summon |